Christopher Booth, MD, Professor in the Departments of Oncology and Medicine as well as a Health Services Researcher, Queen’s University (Canada), brings a different perspective to the show on healthcare policy and where the cancer system may be failing patients. Dr. Booth shares the “desert island” hypothetical scenario he used in a previous publication in which he asked oncologists all over the world for their 10 cancer drugs they would take to the “island” to help their patients. Then, he shares his thoughts on the relatively novel concepts of the “value crisis” and “time toxicity” he sees in cancer care, how to reconcile benefit to individual patients vs patient populations, the translation from efficacy to effectiveness within treatments, ways to temper patient expectations when it comes to hype vs hope for treatments and recovery goals, and a whole lot more.
N/A
Dr. Joe Mikhael, Chief Medical Officer of the International Myeloma Foundation (IMF) and Professor at TGen, takes us beyond his medical career to explore the personal experiences that have shaped his journey in oncology. Dr. Mikhael discusses the IMF’s targeted strategies for reducing health disparities among diverse ethnic and racial groups affected by myeloma, shedding
Tom Beer, Chief Medical Officer of the Multi-Cancer Early Detection (MCED) program at Exact Sciences, delves into the groundbreaking science behind MCED tests, which use advanced biomarkers for early detection of multiple cancer types. On this Healthcare Unfiltered episode, he explains who may be eligible for these tests, how to interpret results to avoid unnecessary
In this special episode, I give up the microphone to guest host Kelly Ryerson, who takes over the show asking questions about my new book “The Cancer Journey.”
